3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole has been researched along with Central Nervous System Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Curtis, MA; Lin, SX; Sperry, J | 1 |
| Anderson, DJ; Arneric, SP; Bannon, AW; Briggs, CA; Brioni, JD; Decker, MW; Donnelly-Roberts, D; Holladay, MW; Sullivan, JP; Williams, M | 1 |
2 review(s) available for 3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole and Central Nervous System Disease
| Article | Year |
|---|---|
Pyridine alkaloids with activity in the central nervous system.
Topics: Alkaloids; Amphibians; Animals; Bacteria; Central Nervous System Diseases; Fungi; Nicotine; Plants; Pyridines; Receptors, Nicotinic | 2020 |
Cholinergic channel activators: novel opportunities for the treatment of CNS disorders.
Topics: Animals; Anti-Anxiety Agents; Benzylidene Compounds; Bridged Bicyclo Compounds, Heterocyclic; Central Nervous System Diseases; Cholinergic Antagonists; Humans; Ion Channels; Isoxazoles; Nicotinic Agonists; Parasympathetic Nervous System; Pyridines; Pyrrolidines; Receptors, Cholinergic | 1995 |